A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05194072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine. A side effect is anything a medicine does to the body besides treating the disease. This study is seeking for participants who either have cancer: * that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable), * has spread through the body (metastatic), or have some cancer left over after surgery. This study will have five parts. * Parts A and B of the study will find out how much Felmetatug Vedotin should be given to participants. * Part C will use the amount found in Parts A and B to find out how safe Felmetatug Vedotin is and if it works to treat solid tumor cancers. * Part D will find out if and how much Felmetatug Vedotin can be given with pembrolizumab. * Part E will use the amount found in Part D to find out how safe Felmetatug Vedotin with pembrolizumab is and if it works to treat triple negative breast cancer.
Study identification
- NCT ID
- NCT05194072
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2022
- Primary completion
- May 13, 2025
- Completion
- May 13, 2025
- Last update posted
- Jan 8, 2026
2022 – 2025
United States locations
- U.S. sites
- 22
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCHealth Sue Anschutz-Rodgers Eye Center | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) | Aurora | Colorado | 80045 | — |
| Presbyterian/St Lukes Medical Center | Denver | Colorado | 80218 | — |
| AdventHealth Celebration Infusion Center | Celebration | Florida | 34747 | — |
| AdventHealth Medical Group Oncology Research at Celebration | Celebration | Florida | 34747 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| Florida Cancer Specialists | Orlando | Florida | 32827 | — |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | — |
| Northwestern Medical Group | Chicago | Illinois | 60611 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Community Health Network, Inc. | Indianapolis | Indiana | 46227 | — |
| Community Health Network, Inc. | Indianapolis | Indiana | 46250 | — |
| Community Health Network, Inc. | Indianapolis | Indiana | 46256 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | 78229 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05194072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05194072 live on ClinicalTrials.gov.